Lotemax: PARS completed two Phase III studies of Lotemax

Pharmos Corp. (PARS), Alachua, Fla. Product: Lotemax, loteprednol etabonate 0.2 percent Indication: Seasonal allergic conjunctivitis Status: PARS completed two Phase III studies of Lotemax, with res...